Lancet Neurol: Acetaminophen, modaphine, and methylphenidate have no significant effect on multiple sclerosis fatigue

Clinically, methylphenidate, modalfinist and amines are often used to relieve fatigue in patients with multiple sclerosis, but there is little evidence to support its efficacy and contradictory evidence.
recently compared the efficacy of these three drugs in patients with multiple sclerosis fatigue.
study was conducted at two academic research centers in the United States, involving patients with multiple sclerosis with an MFIS fatigue score of more than 33 points, who were randomly treated with oral acetaminophen (up to 100 mg twice a day), modapheone (up to 100 mg, twice a day), methamphetamine (up to 10 mg, twice a day) or placebo for up to 6 weeks per drug intervention.
all participants received four interventions in turn, and the main results of the study measured the MFIS score at the maximum to-dosage at week 5 of each drug cycle.
141 patients participated in the study, of whom 35 (25%) received macadamin, placebo, modaphe and methylphenidate, and 34 (24%) received placebo, methylphenidate, methylamine and mo Daphne was treated; 35 (25%) patients were treated with modaphetamine, acetaminophen, methylphenidate and placebo, and 37 (26%) patients were treated with methylphenidate, modaphe, placebo and macadamine sequences.
136 participants were included in the intent therapy analysis.
average of MFIS at baseline examination and maximum to-dosage is as follows: 51.3 at baseline, 40.6 after placebo treatment, 41.3 after macadamine treatment, 39.0 after modaphine treatment, and 38.6 after methamphetamine treatment.
compared to the placebo group (31 per cent), the proportion of adverse events increased after taking acetaminophen (39 per cent), modalfinib (40 per cent) and methylphenidate (40 per cent).
three serious adverse events occurred during the study period (pulmonary embolism and myocarditis in the amine group and a worsening of multiple sclerosis in the Modaphini group that required hospitalization).
study found that amines, modaphines, and methylphenidate were not superior to placebos in improving multiple sclerosis fatigue and led to more frequent adverse events.
the results of this study do not support the treatment of fatigue caused by multiple sclerosis with acetaminophen, modaphine, or methylphenidate.
。